Pazopanib

Drug Profile

Pazopanib

Alternative Names: 786034; Armala; GW-786034; GW-786034B; Pazopanib hydrochloride; SB-786034; Votrient

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Duke University Medical Center; GlaxoSmithKline; Masonic Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; SCRI Development Innovations; University of Minnesota; University of Oxford; University of Washington
  • Class Antineoplastics; Indazoles; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Sarcoma
  • Phase II Acute myeloid leukaemia; Bladder cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Gastrointestinal stromal tumours; Glioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours; Thyroid cancer; Urogenital cancer
  • Phase I/II Malignant melanoma
  • Phase I Colorectal cancer; Hepatocellular carcinoma; Prostate cancer
  • Discontinued Age-related macular degeneration; Hereditary haemorrhagic telangiectasia; Inflammatory breast cancer

Most Recent Events

  • 19 Apr 2017 Discontinued - Phase-II for Hereditary haemorrhagic telangiectasia in USA (PO) (NCT02204371)
  • 19 Apr 2017 GlaxoSmithKline terminates a phase-II trial in Hereditary haemorrhagic telangiectasia in USA (PO) (NCT02204371)
  • 29 Mar 2017 GlaxoSmithKline terminates due to slow accrual its phase II trial in Breast cancer (Neoadjuvant therapy, Combination therapy) in USA (NCT01394211)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top